How Can Relapse Be Prevented and Managed After Hematopoietic Stem Cell Transplantation?

Overview: HSCT can provide long-term remission or a chance of cure for some blood disorders, but relapse can still occur. Long-term management focuses on reducing relapse risk, detecting disease changes as early as possible, and intervening when appropriate. According to the handbook, follow-up may include measurable/minimal residual disease (MRD) monitoring, immune-based approaches, drug therapy, cellular therapy, and other individualized strategies.

Why Can Disease Return After HSCT?

Many patients and families ask, “Once the transplant succeeds, does that mean the disease can never come back?”

Although HSCT can offer long-term remission or even a chance of cure for some patients, it cannot guarantee that relapse will never occur.

Relapse is often associated with small numbers of disease cells remaining in the body after transplantation. If these cells begin to multiply again, the disease may return.

The post-transplant immune environment, the ability of donor immune cells to recognize diseased cells, and the biological characteristics of the underlying disease can also influence relapse risk. Long-term care after transplantation is therefore essential.

What Factors May Affect Relapse Risk?

Several factors can influence the risk of relapse.

First is the disease status before transplantation. For some patients with blood cancers, inadequate disease control before transplantation and a higher burden of residual disease cells may increase the risk of relapse afterward.

Second are the characteristics of the disease itself. Different blood disorders have different patterns of relapse and progression. For example, some diseases with high-risk genetic abnormalities or molecular features require particularly close monitoring and management even after transplantation.

The patient's immune status after transplantation also matters. In allogeneic HSCT, donor immune cells can help fight the disease through the graft-versus-leukemia or graft-versus-tumor (GVL/GVT) effect. If this immune effect is insufficient, disease control may be affected.

How Is Relapse Monitored After Transplantation?

Regular post-transplant follow-up is an important way to detect changes in the disease.

Depending on the underlying disease and individual circumstances, doctors may arrange blood tests, bone marrow examinations, molecular tests, and other assessments.

Minimal residual disease (MRD) testing has become an important tool in the management of blood disorders.

MRD testing can detect very low levels of residual disease cells. Sometimes it identifies abnormal changes before an obvious clinical relapse, providing information that may allow doctors to consider earlier intervention.

Even if you feel well and have no obvious symptoms, it is important to attend follow-up appointments as scheduled.

Can Relapse After Transplantation Still Be Treated?

Yes. Relapse after transplantation does not mean there are no further treatment options.

The treatment plan must be individualized according to factors including:

• The type of disease.

• How soon relapse occurs after transplantation.

• The patient's overall health.

• Treatments received previously.

• The current disease burden.

Depending on the circumstances, doctors may consider drug treatment, targeted therapy, immunotherapy, cellular therapy, or another transplantation.

As new medicines and treatment technologies have developed, some patients who relapse after transplant have been able to achieve another remission with subsequent treatment.

How Can Relapse Risk Be Reduced?

Efforts to reduce relapse risk extend throughout the period before and after transplantation.

Before transplantation, doctors aim to control the underlying disease as effectively as possible so that the patient can proceed to transplant in a more favorable disease state.

After transplantation, regular monitoring helps identify disease changes promptly and allows intervention according to the patient's condition.

For selected patients at high risk of relapse, doctors may consider maintenance therapy, immune-modulating treatment, or other preventive measures to lower the likelihood of recurrence.

Patient participation is also essential: attend follow-up visits, take medications as prescribed, and report changes in your health promptly.

How Can Patients Manage Their Long-Term Health After Transplantation?

Long-term care after HSCT focuses not only on relapse, but also on overall physical recovery.

Follow the monitoring schedule set by your doctor. Do not reduce the frequency of examinations simply because you feel well.

Medication management is also important. Some patients need to take immune-related medications for a prolonged period. Take these exactly as prescribed and do not stop treatment or change the dose on your own.

Contact your doctor if you develop persistent fever, worsening fatigue, abnormal blood counts, or unexplained changes in your body.

Regular daily routines, balanced nutrition, and appropriate exercise can also support long-term recovery.

Summary

Relapse monitoring and management are important components of long-term treatment after HSCT.

Appropriate follow-up, MRD monitoring, timely recognition of disease changes, and individualized use of drug therapy, immunotherapy, or cellular therapy can help reduce the impact of relapse for some patients.

Transplantation is not the end of treatment; it marks the start of a new phase of long-term care. Attending follow-up appointments and maintaining communication with the healthcare team can help protect long-term treatment outcomes.